Sight Sciences is a medical device company focused on surgical tools for two eye diseases: glaucoma and dry eye disease. The dominant business — roughly 98% of revenue — is the Interventional Glaucoma segment, built around the OMNI Surgical System, a single-use handheld device that lets surgeons perform a microinvasive glaucoma surgery (MIGS) procedure to reduce intraocular pressure in glaucoma patients. OMNI is used primarily in ambulatory surgery centers and hospital outpatient departments, often alongside cataract surgery. A secondary product, SION, serves surgeons who prefer a simpler procedure. The smaller Interventional Dry Eye segment sells TearCare, a wearable eyelid device that applies heat to unblock meibomian glands — the underlying cause of evaporative dry eye — in a clinic setting rather than a surgical suite. Sight Sciences' business model is driven by single-use consumable sales to hospitals, surgery centers, and physician practices, with revenue tied to the number of ordering accounts, procedures per account, and selling price per unit. Gross margins are high, as the consumable products carry low direct manufacturing costs. The company sells directly to eye care providers in the U.S., UK, and Germany, with distributors elsewhere in Europe. Sight Sciences is not yet profitable. The key growth levers are expanding OMNI's use in standalone glaucoma procedures and establishing Medicare reimbursement for TearCare, where two MAC jurisdictions set fee schedules in late 2025 — a development management views as the start of a reimbursed market for interventional dry eye.